- Home
- REFI vs CCCC Comparison
REFI vs CCCC Comparison
Compare REFI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | CCCC |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 240.3M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REFI | CCCC |
|---|---|---|
| Price | $12.81 | $2.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $20.00 | $8.50 |
| AVG Volume (30 Days) | 103.0K | ★ 1.4M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 15.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $54,287,847.00 | $30,108,000.00 |
| Revenue This Year | $13.78 | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $7.95 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.85 | $1.09 |
| 52 Week High | $16.29 | $4.70 |
Technical Indicators
Market Signals| Indicator | REFI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 46.82 |
| Support Level | $12.60 | $2.50 |
| Resistance Level | $13.49 | $2.69 |
| Average True Range (ATR) | 0.29 | 0.18 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 38.21 | 10.21 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.